Iveric bio, inc. (ISEE)

CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Operating Activities
Net Income (Loss) Attributable to Parent

-61,434

-58,859

62,733

62,425

63,659

63,087

-50,569

153,249

144,254

114,205

57,464

-192,500

-200,241

-193,420

-162,786

-141,468

-148,654

-105,717

0

0

0

-

-

0

0

Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and other expense

157

162

167

172

176

183

960

1,501

2,042

2,800

2,240

1,841

1,430

800

702

591

820

698

582

543

171

127

0

0

0

Amortization of premium and discounts on investment securities

-

-

-

-

-

-

-

-

-

-140

-281

-401

-497

-595

-783

-1,109

-2,051

-2,846

0

0

0

-

-

-

-

Deferred income taxes

-

-

-

-

-

0

-3,296

-3,125

-3,133

-3,366

201

93

-159

22,954

0

0

0

-

-

-

-

-

-

-

-

Share-based compensation

9,034

9,180

9,527

10,005

10,460

11,072

12,056

12,863

15,189

18,171

21,234

26,071

29,392

31,660

31,175

29,968

28,038

24,760

22,022

18,561

15,365

13,040

0

0

0

Changes in operating assets and liabilities:
Due from Novartis Pharma AG

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6

29,950

-40,187

3,429

0

0

0

-

-

-

-

Income tax receivable

1,177

-1,765

-1,635

1

0

-1,387

-52

-52

-52

1,387

-24,213

-24,232

-26,445

-3,421

0

0

0

-

-

-

-

-

-

-

-

Prepaid expense and other assets

-

-

-

-

-

-

-

-1,205

-2,200

-370

-130

790

2,299

995

-558

-5,520

-3,132

-3,260

0

0

0

-

-

-

-

Prepaid expense and other assets

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Accrued interest receivable

-

-

-

-

-

-

-

-

-

-466

-511

-331

-277

-203

8

129

-602

-155

0

0

0

-

-

-

-

Other assets

-

-

-

-

-

-

-

0

37

-

-443

-446

-497

-27

153

158

139

107

0

0

0

-

-

-

-

Accrued research and development expenses

2,474

-477

-966

2,508

714

2,353

-296

-7,550

-22,759

-42,256

-33,805

-12,464

6,228

28,420

19,937

15,376

13,624

10,902

13,738

7,992

5,301

5,433

0

0

0

Accounts payable and accrued expenses

-613

-241

-948

-753

-291

-1,682

-3,281

-2,274

-5,379

-4,481

-2,494

-1,501

1,370

14

2,539

1,619

1,530

3,311

1,144

2,111

2,004

4,897

0

0

0

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

0

-3,293

-

-2,942

-2,918

-6,338

3,442

0

0

0

-

-

-

-

Net cash used in operating activities

-51,413

-48,490

-46,663

-45,256

-44,426

-41,911

-45,074

-50,325

-72,397

-121,821

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-83,762

-

-28,728

-49,535

95,725

111,088

0

0

0

Investing Activities
Purchase of marketable securities

-

-

-

-

-

-

-

-

-

12,014

36,088

72,208

72,206

72,197

76,767

201,650

279,137

411,565

595,280

574,856

517,948

597,762

0

0

0

Maturities of marketable securities

-

-

-

-

-

-

-

-

-

166,806

190,806

147,459

108,619

86,500

62,500

85,500

102,000

266,000

0

0

0

-

-

-

-

Purchase of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

572

1,286

2,045

2,613

2,615

1,889

1,532

991

1,655

0

0

0

Net cash provided by (used in) investing activities

150

150

150

0

0

0

0

55,347

134,687

154,792

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

216,233

-

137,480

-213,782

-173,339

-427,817

0

0

0

Financing Activities
Proceeds from employee stock plan purchases

411

273

81

79

79

65

65

52

67

71

0

0

0

-

-

-

-

11,473

7,752

6,861

4,698

2,949

0

0

0

Proceeds from follow-on public offering, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

55,409

0

0

0

Proceeds from stock option/employee stock purchase plan exercises

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Net cash provided by financing activities

42,976

42,838

6,156

6,154

6,154

6,140

65

52

67

71

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net change in cash and cash equivalents

-8,287

-5,502

-40,357

-39,102

-38,272

-35,771

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net change in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from royalty purchase agreement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

83,333

0

0

0

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

11,783

-

51,339

51,539

50,620

145,947

0

0

0

Net change in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

144,254

-

160,091

-211,778

-26,994

-170,782

0

0

0

Supplemental disclosure of cash paid
Income taxes received, net

-

-

-

-

-

-2,467

2,222

2,222

-1,670

-245

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental disclosures of non-cash information related to investing activities
Change in unrealized loss on available for sale securities, net of tax

-

-

-

-

-

-

-

-

-

-

-

0

-226

-

-238

-142

21

-408

44

-1

-35

-65

0

0

0